The Galien Foundation Announces 2022 Prix Galien USA Nominees in "Best Biotechnology Product," "Best Pharmaceutical Agent" and "Best Medical Technology" Categories

-- Winners to be Recognized by Committee of Distinguished Scientific Leaders on October 27, 2022, at the Prix Galien USA Awards Ceremony in New York City

NEW YORK, July 26, 2022 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the 2022 Prix Galien USA Award nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology." Winners will be announced during the Prix Galien USA Awards Ceremony on October 27, 2022, at the American Museum of Natural History in New York City.

"Every year, evaluating and recognizing the amazing submissions that come through for the Prix Galien Awards is one of the greatest honors," said Dr. Sue Desmond-Hellmann, Chair of the Prix Galien USA and Prix Galien International Award Committees and former CEO of the Bill & Melinda Gates Foundation. "The commitment and dedication of the innovators who develop these products never cease to amaze the awards committee, and we are excited to announce the 2022 nominations."

The 2022 Prix Galien USA nominees include products evaluated in the following categories: "Best Biotechnology Product" – 22 nominees; "Best Pharmaceutical Agent" – 33 nominees; and "Best Medical Technology" – 24 nominees.

To qualify, each candidate must be U.S. Food and Drug Administration (FDA) approved for marketing within the last five years and demonstrate tremendous potential to improve human health. Sales data are not considered by the nominating committee in their award nominee selection, only science and health impact.

Best Biotechnology Product (Nominees)

Best Pharmaceutical Agent (Nominees)

Best Medical Technology (Nominees)

"I am grateful the Prix Galien Awards provide the opportunity to recognize excellence in biopharmaceutical and medical technology innovations that improve the human condition," said Bruno Cohen, Chairman of The Galien Foundation. "We look forward to displaying these nominees and all of their accomplishments on center stage during a wonderful celebration."

The Prix Galien USA Awards Committee is composed of 10 renowned leaders from the biomedical industry and academia, including two Nobel Laureates, responsible for evaluating nominees.

Prix Galien Awards Committee 2022

Sue DESMOND-HELLMANN
M.D., M.P.H., Former Chief Executive Officer, Bill & Melinda Gates Foundation
Committee Chair

Richard AXEL
M.D., Nobel Laureate, Co-director, The Kavli Institute for Brain Science; Professor, Columbia University Medical Center

Linda BUCK
Ph.D., Nobel Laureate, Fred Hutchinson Cancer Research Center member; Professor of Physiology and Biophysics, University of Washington

Laurie GLIMCHER
M.D., President and CEO, Dana Farber Cancer Institute, Professor of Medicine, Harvard Medical School

Mary-Claire KING
Ph.D., American Cancer Society Professor of Genome Sciences and Medical Genetics, University of Washington

Robert S. LANGER
M.D., David H. Koch Institute Professor, Massachusetts Institute of Technology

Cato T. LAURENCIN
M.D., Ph.D. University Professor, University of Connecticut

Steven J. LESTER
M.D., Chief Medical Officer, Mayo Clinic-ASU MedTech Accelerator

Michael ROSENBLATT
M.D., Chief Medical Officer, Flagship Pioneering

Marc TESSIER-LAVIGNE
Ph.D., President, Stanford University

Elie WIESEL
Nobel Peace Prize Laureate, Boston University, Honorary Founding President, In Memoriam

The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatments and technologies that will impact the state of medical practice and save lives.

The Foundation oversees and directs activities in the US for the Prix Galien, an international awards program dedicated to progress through innovative medicines development, with chapters in 14 countries and Africa. The Prix Galien was created in 1970 by Roland Mehl in honor of Galien, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.

For more information, visit www.galienfoundation.org.

Follow the Foundation on social media: https://www.facebook.com/GalienFoundation/ 
https://twitter.com/GalienFdn
https://www.linkedin.com/company/the-galien-foundation/

Media Contact:
Kara Bradley
Finn Partners [email protected]
646-213-7243

SOURCE The Galien Foundation